Photo Credit: PexelsPhoto Credit:

EMGALITY™ (galcanezumab) now available in Canada for preventive treatment of migraine


Thursday, 03 October 2019 06:25.PM

- New anti-CGRP treatment for the prevention of migraine in adults with at least 4 migraine days per month. -

(Eli Lilly Canada) - Eli Lilly Canada Inc. (Lilly Canada) is pleased to announce the availability of Emgality™ (galcanezumab) in Canada. Emgality is indicated for the prevention of migraine in adults who have at least 4 migraine days per month.

Migraine is a complex neurological disease that has a crippling effect on the lives of nearly three million Canadians, and globally migraine was the second leading cause of disability in 2016. Living with migraine results in collateral damage on all aspects of life – its debilitating physical effects impact work, social life, relationships and mental well-being.

"Every day in the clinic I meet people who suffer with debilitating migraines that impact their quality of life. Migraine-specific medications that work to prevent and ultimately reduce migraine days are needed to treat this disease," says Dr. Elizabeth Leroux, Headache Neurologist in Montreal and President of the Canadian Headache Society. "Clinical data show that treatment with Emgality may significantly reduce migraine days for these patients. This is good news."

"Migraine is a complex disease that impacts patients in many different ways. The research on CGRP has led to a new class of migraine preventives for Canadians living with episodic and chronic migraine," said Jillian Reardon, Secretary of Migraine Canada and pharmacist in British Columbia. "CGRP antibodies may help those who need relief from the pain and associated symptoms of migraine. Migraine Canada welcomes new treatments, like galcanezumab, that may improve the lives of Canadians with migraine."